BMJ Open (Jul 2019)

Glycaemic, blood pressure and low-density lipoprotein-cholesterol control among patients with diabetes mellitus in a specialised clinic in Botswana: a cross-sectional study

  • Brian Godman,
  • Joel M Francis,
  • Julius Chacha Mwita,
  • Bernard Omech,
  • Elizabeth Botsile,
  • Aderonke Oyewo,
  • Matshidiso Mokgwathi,
  • Onkabetse Julia Molefe-Baikai,
  • Jose-Gaby Tshikuka

DOI
https://doi.org/10.1136/bmjopen-2018-026807
Journal volume & issue
Vol. 9, no. 7

Abstract

Read online

Objective Control of glycaemic, hypertension and low-density lipoprotein-cholesterol (LDL-C) among patients with type 2 diabetes mellitus (T2DM) is vital for the prevention of cardiovascular diseases. The current study was an audit of glycaemic, hypertension and LDL-C control among ambulant patients with T2DM in Botswana. Also, the study aimed at assessing factors associated with attaining optimal glycaemic, hypertension and LDL-C therapeutic goals.Design A cross-sectional study.Setting A specialised public diabetes clinic in Gaborone, Botswana.Participants Patients with T2DM who had attended the clinic for ≥3 months between August 2017 and February 2018.Primary outcome measure The proportion of patients with optimal glycaemic (HbA1c<7%), hypertension (blood pressure <140/90 mm Hg) and LDL-C (<1.8 mmol/L) control.Results The proportions of patients meeting optimal targets were 32.3% for glycaemic, 54.2% for hypertension and 20.4% for LDL-C. Age≥ 50 years was positively associated with optimal glycaemic control (adjusted OR [AOR] 5.79; 95% CI 1.08 to 31.14). On the other hand, an increase in diabetes duration was inversely associated with optimal glycemic control (AOR 0.91; 95% CI 0.85 to 0.98). Being on an ACE inhibitor was inversely associated with optimal hypertension control (AOR 0.35; 95% CI 0.14 to 0.85). Being female was inversely associated with optimal LDL-C control (AOR 0.24; 95% CI (0.09 - 0.59).Conclusion Patients with T2DM in Gaborone, Botswana, presented with suboptimal control of recommended glycaemic, hypertension and LDL-C targets. These findings call for urgent individual and health systems interventions to address key determinants of the recommended therapeutic targets among patients with diabetes in this setting.